Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 12/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | THRA | P10827 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5936325 | 0.99 | KDM4E (0.52) | KDM4EACHEALDH1A1EPHX1THRA | |
| Hydrochloric Acid SCHEMBL2672972 | 0.97 | KDM4E (0.51) | KDM4EACHEALDH1A1EPHX1THRA | |
| SCHEMBL8587343 | 0.86 | ACHE (0.61) | KDM4EACHEALDH1A1EPHX1 | |
| SCHEMBL9849366 | 0.81 | ACHE (0.66) | ACHEEPHX1 | |
| SCHEMBL11730144 | 0.76 | KDM4E (0.61) | KDM4EALDH1A1EPHX1 | |
| SCHEMBL7199880 | 0.76 | ACHE (0.58) | KDM4EACHEEPHX1 | |
| SCHEMBL26578213 | 0.76 | ACHE (0.58) | ACHETHRATHRB | |
| SCHEMBL8589907 | 0.76 | ACHE (0.58) | ACHETHRATHRB | |
| SCHEMBL5936371 | 0.75 | LMNA (0.47) | ACHEEPHX1 | |
| SCHEMBL20363766 | 0.75 | ALDH1A1 (0.53) | KDM4EACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888514-B1 | SALTS OF SUBSTITUTED ALLOPHANATES AND THEIR USE IN DRUGS | GRUENENTHAL GMBH (DE) | 2009-03-18 | — | — | EP | claimed |
| US-20090062383-A1 | Salts of Substituted Allophanates and Their Use in Drugs | GRUENENTHAL GMBH (DE) | 2009-03-05 | — | — | US | claimed |
| US-8173700-B2 | Salts of substituted allophanates and their use in drugs | GRUENENTHAL GMBH (DE) | 2012-05-08 | — | — | US | disclosed |
| US-20090062383-A1 | Salts of Substituted Allophanates and Their Use in Drugs | GRUENENTHAL GMBH (DE) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062383-A1 | Salts of Substituted Allophanates and Their Use in Drugs | SLC10A1, SLC10A6, SLC5A1 | ACHE 1367/4885KDM4E 3187/4885ALDH1A1 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.